Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma

Despite the increasing number of treatment options available for multiple myeloma, relapse is still inevitable and there remains a critical unmet need for treatments for patients with late-stage, highly refractory disease. In this review, we discuss currently approved treatment options for heavily p...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Clinical lymphoma, myeloma and leukemia Ročník 22; číslo 7; s. 460 - 473
Hlavní autori:	Dimopoulos, Meletios-Athanasios, Richardson, Paul, Lonial, Sagar
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States Elsevier Inc 01.07.2022
Predmet:	Anti-CD38 antibody Elotuzumab Heavily pretreated Immunomodulatory drugs Monoclonal antibodies Multiple myeloma Pomalidomide Proteasome inhibitors Relapsed/refractory Immunomodulatory drugs Multiple myeloma Heavily pretreated Monoclonal antibodies Anti-CD38 antibody Pomalidomide Relapsed/refractory Proteasome inhibitors Elotuzumab
ISSN:	2152-2650, 2152-2669, 2152-2669
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!